首页 | 本学科首页   官方微博 | 高级检索  
检索        

淋巴组织表达受体在食管鳞状细胞癌中表达水平与临床病理参数及预后的关系
引用本文:李赛赛,姚文健,王建军,李基伟,张全,魏立.淋巴组织表达受体在食管鳞状细胞癌中表达水平与临床病理参数及预后的关系[J].中华实用诊断与治疗杂志,2021(2).
作者姓名:李赛赛  姚文健  王建军  李基伟  张全  魏立
作者单位:郑州大学人民医院河南省人民医院胸外科
基金项目:河南省人民医院“23456人才工程”科研专项基金;河南省科技厅发展攻关项目(202102310457)。
摘    要:目的观察淋巴组织表达受体(receptor expressed in lymphoid tissue, RELT)在食管鳞状细胞癌组织中的表达水平,探讨其与临床病理参数及预后的关系。方法食管鳞状细胞癌患者83例,取手术切除的鳞状细胞癌组织和癌旁正常组织标本,采用实时荧光定量PCR法检测2种组织RELT mRNA相对表达量,采用免疫组织化学法检测2种组织RELT蛋白阳性表达率,采用Western blot法检测2种组织RELT蛋白相对表达量。根据RELT mRNA相对表达量中位数将患者分为低表达组42例和高表达组41例,比较2组临床资料,采用Kaplan-Meier生存分析比较2组患者无病生存期;采用多因素COX比例风险回归模型分析食管鳞状细胞癌患者预后不良的危险因素。结果食管鳞状细胞癌组织RELT mRNA(8.022±2.301)、RELT蛋白(0.867±0.085)相对表达量及RELT蛋白阳性表达率(78.31%)均高于癌旁正常组织(3.080±0.754、0.634±0.123、16.87%)(P<0.05);高表达组患者年龄<60岁(68.29%)、T3~T4期(75.61%)、TNM分期ⅡB~Ⅲ期(68.29%)、有淋巴结转移(58.54%)和脉管侵犯(63.41%)发生率高于低表达组(38.10%、45.24%、42.86%、26.19%、28.57%)(P<0.05);高表达组患者中位无病生存期(16个月)短于低表达组(>30个月)(P<0.05);RELT mRNA相对表达量≥8.009(HR=2.120,95%CI:1.102~4.078,P=0.024)、TNM分期ⅡB~Ⅲ期(HR=36.348,95%CI:2.202~599.976,P=0.012)是食管鳞状细胞癌患者预后不良的危险因素。结论食管鳞状细胞癌患者RELT高表达与不良预后有关,可能参与食管鳞状细胞癌的发生和发展过程。

关 键 词:食管鳞状细胞癌  淋巴组织表达受体  生存分析  预后

Relationships of receptor expressed in lymphoid tissues in esophageal squamous cell carcinoma with clinicopathological parameters and prognosis
LI Sai-sai,YAO Wen-jian,WANG Jian-jun,LI Ji-wei,ZHANG Quan,WEI Li.Relationships of receptor expressed in lymphoid tissues in esophageal squamous cell carcinoma with clinicopathological parameters and prognosis[J].Journal of Chinese Practical Diagnosis and Therapy,2021(2).
Authors:LI Sai-sai  YAO Wen-jian  WANG Jian-jun  LI Ji-wei  ZHANG Quan  WEI Li
Institution:(Department of Thoracic Surgery,Zhengzhou University People's Hospital,Henan Provincial People's Hospital,Zhengzhou,Henan 450003,China)
Abstract:Objective To observe the expression level of receptor expressed in lymphoid tissues(RELT) in esophageal squamous cell carcinoma tissues, and to investigate its relationships with clinicopathological parameters and prognosis. Methods Real-time fluorescence quantitative PCR was used to detect the relative expression of RELT mRNA in resected squamous cell carcinoma cancer tissues and adjacent normal tissues from 83 cases of esophageal squamous cell carcinoma. The positive rate of RELT protein was detected by immunohistochemistry. The relative expression of RELT protein was detected by Western blot. According to the median relative expression of RELT mRNA, 83 patients were divided into low-expression group(n=42) and high-expression group(n=41). The clinical data of two groups were compared, and the disease-free survival time was compared by Kaplan-Meier survival analysis between two groups. The COX proportional hazard was used to analyze the risk factors of poor prognosis of esophageal squamous cell carcinoma. Results The relative expressions of RELT mRNA(8.022±2.301) and RELT protein(0.867±0.085) as well as the positive rate of RELT protein(78.31%) in esophageal squamous cell carcinoma tissues were higher than those in adjacent normal tissues(3.080±0.754, 0.634±0.123, 16.87%)(P<0.05). The percentages of patients <60 years(68.29%), in T3-T4 stage(75.61%), in TNM stage ⅡB-Ⅲ(68.29%), with lymph node metastasis(58.54%) and vascular invasion(63.41%) in high-expression group were higher than those in low-expression group(38.10%, 45.24%, 42.86%, 26.19%, 28.57%)(P<0.05). The median disease-free survival time was shorter in high-expression group(16 months) than that in low-expression group(>30 months)(P<0.05). The relative expression of RELT mRNA ≥8.009(HR=2.120, 95%CI: 1.102-4.078, P=0.024), and TNM stageⅡB-Ⅲ(HR=36.348,95%CI:2.202-599.976,P=0.012)were the risk factors of poor prognosis of esophageal squamous cell carcinoma.Conclusion The high expression of RELT in patients with esophageal squamous cell carcinoma is associated with poor prognosis,and may be involved in the occurrence and development of esophageal squamous cell carcinoma.
Keywords:esophageal squamous cell carcinoma  receptor expressed in lymphoid tissues  survival analysis  progntsis
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号